Linked Life Data

2222818

Source:http://linkedlifedata.com/resource/pubmed/id/2222818

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1990-12-5
pubmed:abstractText
Sixteen children with hGH deficiency were treated for a year with methionyl-somatotropin (Somatonorm) or recombinant-somatotropin (Genotropin). The hormone was administrated subcutaneously 3 time/week, 0.45-0.6 IU/kg/week. After a year of treatment, the mean growth rate in those who received Somatonorm increased from 3.96 +/- 0.8 cm/yr to 9.08 +/- 2.7 cm/yr, and in those who received Genotropin from 3.6 +/- 0.6 cm/yr to 8.58 +/- 1.1 cm/yr with no significant difference. No adverse effects were observed, but four children that received Somatonorm developed antihGH antibodies with a very low binding capacity, of less than 0.1 mg/L. All the children that received Genotropin were negative for antihGH antibodies.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0539-6115
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
369-71
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
[Results of the treatment of growth hormone deficiency with methionine-somatotropin or recombinant somatotropin].
pubmed:affiliation
Departamento de Endocrinología Hospital Infantil de México Federico Gómez, México.
pubmed:publicationType
Journal Article, English Abstract